Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
645 studies found for:    "Burkitts lymphoma"
Show Display Options
Rank Status Study
1 Completed Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma
Conditions: Burkitt Lymphoma;   B-ALL
Intervention: Drug: Chemotherapy-Rituximab combination
2 Terminated
Has Results
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma
Conditions: Burkitt Lymphoma;   Non-Hodgkins Lymphoma;   Atypical Burkitt Lymphoma
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Methotrexate;   Drug: Leucovorin;   Drug: Ifosfamide;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Mesna
3 Completed Rituximab Combined With Chemotherapy in Burkitt`s Lymphoma
Conditions: Acute Lymphoblastic Leukemia;   Burkitt's Lymphoma
Intervention: Drug: RITUXIMAB
4 Unknown  Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma
Conditions: HIV;   Burkitt's Lymphoma
Interventions: Drug: Induction Phase;   Drug: Consolidation Phase (on day +50);   Drug: Intensification phase;   Drug: BEAM conditioning;   Radiation: Consolidation radiotherapy
5 Unknown  LMBA02 Protocol for Patients With a Burkitt Lymphoma
Condition: Burkitt Lymphoma
Intervention: Drug: rituximab
6 Terminated Rituximab in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL
Condition: Burkitt Lymphoma
Intervention: Drug: Rituximab
7 Suspended Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Conditions: Burkitt Lymphoma;   Diffuse Large B-cell Lymphoma, c-MYC Positive;   Plasmablastic Lymphoma
Interventions: Drug: EPOCH-R;   Drug: EPOCH-RR
8 Completed Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia
Condition: B-cell Acute Lymphoblastic Leukemia
Intervention: Drug: forodesine hydrochloride (BCX-1777)
9 Recruiting The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
Condition: B-cell Acute Lymphoblastic Leukemia
Interventions: Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: CART-19 cells
10 Recruiting T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Condition: Relapsed B-Cell Acute Lymphoblastic Leukemia
Interventions: Procedure: leukapheresis or collection of PBMCs;   Drug: cyclophosphamide based chemotherapy regimens;   Biological: modified T cells
11 Unknown  Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
Conditions: Burkitt's Lymphoma;   High-grade B-cell Lymphoma
Intervention: Other: No intervention (observational study)
12 Completed
Has Results
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
Condition: Lymphoma
Interventions: Biological: filgrastim;   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: liposomal cytarabine;   Drug: methotrexate;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
13 Recruiting Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)
Conditions: Lymphoma, Non-Hodgkin;   Malaria;   Herpesvirus 4, Human
Intervention:
14 Not yet recruiting Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL
Condition: CD22+ Relapsed/Refractory B-ALL
Interventions: Drug: 90Y-epratuzumab tetraxetan;   Drug: chemotherapy/ immunotherapy
15 Withdrawn Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
Conditions: Relapsed or Refractory Acute Myeloid Leukemia;   Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Intervention: Drug: VS-4718
16 Completed
Has Results
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Conditions: Leukemia;   Lymphoma
Interventions: Biological: filgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: Allopurinol
17 Unknown  Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL)
Condition: Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia
Interventions: Biological: humanised monoclonal antibody, veltuzumab;   Biological: humanised monoclonal antibody epratuzumab;   Biological: humanised monoclonal antibodies veltuzumab and epratuzumab
18 Completed Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults
Conditions: Burkitt's Lymphoma;   Burkitt's Leukemia;   Mediastinal Neoplasms;   Lymphoblastic Lymphoma;   Large Cell Anaplastic Lymphoma
Interventions: Drug: Adriamycin;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone/Prednisolone;   Drug: VP16;   Drug: Ifosfamide;   Drug: Methotrexate;   Drug: G-CSF;   Drug: Rituximab;   Drug: Vincristine/Vindesine;   Procedure: Irradiation (in specific conditions)
19 Completed Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
Conditions: Burkitt's Lymphoma;   Burkitt'S-like Lymphoma
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: G-CSF;   Drug: Cytarabine;   Drug: Methotrexate
20 Recruiting Burkitt Leukemia - Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Ofatumumab (EPOCH - O)
Condition: Leukemia
Interventions: Drug: Ofatumumab;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Rituximab;   Drug: Pegfilgrastim;   Drug: G-CSF;   Behavioral: Phone Calls

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.